Vera Therapeutics
VERAVera Therapeutics is a late clinical-stage biotechnology company dedicated to developing and commercializing transformative treatments for serious immunological diseases.
Earnings
Next report
Aug 4, 2026 (In 6 days)Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Vera Therapeutics is a late clinical-stage biotechnology company dedicated to developing and commercializing transformative treatments for serious immunological diseases. The company's core value proposition centers on its lead product candidate, atacicept, a potential first-in-class dual inhibitor of BAFF and APRIL cytokines designed to modify the underlying disease drivers of autoimmune kidney conditions. By targeting the source of autoantibody production, the company aims to replace non-specific immunosuppressive standards of care with targeted, disease-modifying biologics.
Vera is a late-stage clinical developer positioning its lead candidate as a best-in-class, disease-modifying B-cell modulator for IgA nephropathy.
Questions, answered.
- What is Vera Therapeutics's market cap?
- Vera Therapeutics (VERA) has a market capitalization of $2.5B and trades on NASDAQ.
- Who are Vera Therapeutics's competitors?
- Vera Therapeutics's key competitors include Travere Therapeutics, Inc., Aurinia Pharmaceuticals Inc., Vertex Pharmaceuticals, and others. These companies compete in similar markets and product categories.
- Who does Vera Therapeutics partner with?
- Vera Therapeutics's notable partners include Ares Trading S.A., Merck KGaA, Novartis International Pharmaceutical AG, and others.
- Where is Vera Therapeutics headquartered?
- Vera Therapeutics is headquartered in United States of America and employs approximately 55 people. It has been publicly traded since 2021.